References
- MeredithIRothmanMErglisAE-Five InvestigatorsExtended follow-up safety and effectiveness of the Endeavor zotarolimus-eluting stent in real-world clinical practice: two-year follow-up from the E-Five RegistryCatheter Cardiovasc Interv201177993100020853351
- FajadetJWijnsWLaarmanGJLong-term follow-up of the randomised controlled trial to evaluate the safety and efficacy of the zotarolimus-eluting driver coronary stent in de novo native coronary artery lesions: five year outcomes in the ENDEAVOR II studyEuro Intervention2010656256721044908
- SerruysPOngAPiekJJA randomized comparison of a durable polymer everolimus-eluting stent with a bare metal coronary stent: The SPIRIT first trialEuro Intervention20051586519758878
- TsuchidaKGarcia-GarciaHMOngATRevisiting late loss and neointimal volumetric measurements in a drug-eluting stent trial: analysis from the SPIRIT FIRST trialCatheter Cardiovasc Interv20066718819716400664
- KandzariDELeonMBPopmaJJComparison of zotarolimus eluting and sirolimus-eluting stents in patients with native coronary artery disease: a randomized controlled trialJ Am Coll Cardiol2006482440244717174180
- LeonMBEndeavor clinical trial program Available from: http://www.crtonline.org/flash.aspx?PAGE_ID=4728Accessed October 16, 2007
- StoneGWMideiMNewmanWSPIRIT III InvestigatorsRandomized comparison of everolimus-eluting and paclitaxel-eluting stents: two-year clinical follow-up from the Clinical Evaluation of the Xience V Everolimus Eluting Coronary Stent System in the Treatment of Patients with de novo Native Coronary Artery Lesions (SPIRIT) III trialCirculation200911968068619171853
- HerradorJAFernandezJCGuzmanMComparison of zotarolimus-versus everolimus-eluting stents in the treatment of coronary bifurcation lesionsCatheter Cardiovasc Interv2011781086109221793165
- SerruysPWSilberSGargSComparison of zotarolimus eluting and everolimus-eluting coronary stentsN Engl J Med201036313614620554978
- LeonMLBCT III, Session 3014Presented at the American College of Cardiology 60th Annual Scientific SessionsApril 2–5, 2011New Orleans, LA
- Food and Drug AdministrationCirculatory System Devices Panel Meeting Available from: http://www.fda.gov/ohrms/dockets/ac/cdrh06.html#circulatoryAccessed February 9, 2007
- BrenerSJPrasadAJKhanZSacchiTJThe relationship between late lumen loss and restenosis among various drug-eluting stents: a systematic review and meta-regression analysis of randomized clinical trialsAtherosclerosis201121415816221122853
- LeonMBMauriLPopmaJJENDEAVOR IV InvestigatorsA randomized comparison of the ENDEAVOR zotarolimus-eluting stent versus the TAXUS paclitaxel-eluting stent in de novo native coronary lesions 12-month outcomes from the ENDEAVOR IV trialJ Am Coll Cardiol20105554355420152559
- LeonMBNikolskyECutlipDEENDEAVOR IV InvestigatorsImproved late clinical safety with zotarolimus-eluting stents compared with paclitaxel-eluting stents in patients with de novo coronary lesions: 3-year follow-up from the ENDEAVOR IV (Randomized Comparison of Zotarolimus- and Paclitaxel-Eluting Stents in Patients With Coronary Artery Disease) trialJACC Cardiovasc Interv201031043105020965463
- HermillerJBNikolskyELanskyAJClinical and angiographic outcomes of elderly patients treated with everolimus-eluting versus paclitaxel-eluting stents: three-year results from the SPIRIT III randomised trialEuro Intervention2011730731321729832
- GénéreuxPPalmeriniTCaixetaASYNTAX score reproducibility and variability between interventional cardiologists, core laboratory technicians, and quantitative coronary measurementsCirc Cardiovasc Interv2011455356122028472